Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01411800 · ClinicalTrials.gov registry record · Phase 1
An Open-Label Study of Two Formulations of LX1033 in Healthy Human Subjects
A Phase 1 study, sponsored by Lexicon Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
NCT01411800 is a Phase 1 study that has completed, run by Lexicon Pharmaceuticals. The registered enrollment target is 28 participants.
The verdict
NCT01411800, a Phase 1 study, has completed, sponsored by Lexicon Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the pharmacodynamic effects, pharmacokinetics, and safety of two oral formulations (tablet and capsule) of LX1033 in normal healthy volunteers.
Interventions
- DRUG 250 mg capsule
- DRUG 250 mg tablets
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2011-08 |
| Est. Completion | 2012-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01411800
The ClinicalTrials.gov registry entry for NCT01411800 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Lexicon Pharmaceuticals, which has 56 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which 250 mg capsule is the first listed.
NCT01411800 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01411800 about?
NCT01411800 is a clinical study titled "An Open-Label Study of Two Formulations of LX1033 in Healthy Human Subjects". The purpose of this study is to assess the pharmacodynamic effects, pharmacokinetics, and safety of two oral formulations (tablet and capsule) of LX1033 in normal healthy volunteers.
What is the current status of trial NCT01411800?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2011-08. Estimated completion is 2012-05.
What interventions are being tested in trial NCT01411800?
The interventions under investigation include: 250 mg capsule (DRUG), 250 mg tablets (DRUG).
Who is sponsoring clinical trial NCT01411800?
This trial is sponsored by Lexicon Pharmaceuticals, which has 56 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.